GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Biosciences Inc (NAS:CBIO) » Definitions » Debt-to-Equity

Catalyst Biosciences (Catalyst Biosciences) Debt-to-Equity : 0.00 (As of Sep. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Catalyst Biosciences Debt-to-Equity?

Catalyst Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Catalyst Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Catalyst Biosciences's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $3.52 Mil. Catalyst Biosciences's debt to equity for the quarter that ended in Sep. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Catalyst Biosciences's Debt-to-Equity or its related term are showing as below:

CBIO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0.03   Max: 1.51
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Catalyst Biosciences was 1.51. The lowest was 0.00. And the median was 0.03.

CBIO's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs CBIO: 0.01

Catalyst Biosciences Debt-to-Equity Historical Data

The historical data trend for Catalyst Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Biosciences Debt-to-Equity Chart

Catalyst Biosciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.03 0.02 0.06 -

Catalyst Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - - - -

Competitive Comparison of Catalyst Biosciences's Debt-to-Equity

For the Biotechnology subindustry, Catalyst Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Biosciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Catalyst Biosciences's Debt-to-Equity falls into.



Catalyst Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Catalyst Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Catalyst Biosciences's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Catalyst Biosciences  (NAS:CBIO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Catalyst Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Catalyst Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Biosciences (Catalyst Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
611 Gateway Boulevard, Suite 710, South San Francisco, CA, USA, 94080
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.
Executives
Han Ying director 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Charles C Wu director, officer: Chief Executive Officer 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Songjiang Ma director, officer: President 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Weiguo Ye officer: Chief Operating Officer 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Renate Parry director 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Ruoyu Chen officer: Interim CFO 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Gordon Carmichael director 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Gni Usa, Inc. 10 percent owner 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Augustine Lawlor director 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Andrea Hunt director 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Seline E. Miller officer: SVP Finance; Interim CFO & PAO C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Gni Hong Kong Ltd 10 percent owner 12/F ELITE CENTRE, 22 HUNG TO ROAD, KWUN TONG KL K3 0000
Gni Group Ltd. 10 percent owner NIHONBASHI-HONCHO YS BLDG 3F, 2-2-2 NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-0023
Thomas Wilson Eastling director 17520 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Ying Luo director NIHONBASHI-HONCHO YS BLDG 3F, 2-2-2 NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-0023